Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Next Previous
Trial Profile

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 203CD8 (Primary) ; IMA-203 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Solid tumours; Synovial sarcoma; Triple negative breast cancer; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms ACTengine
  • Sponsors Immatics US

Most Recent Events

  • 31 May 2025 Results presented in the Immatics Media Release
  • 23 Apr 2025 According to an Immatics media release, Company will present updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30-June 3, 2025, in Chicago, Illinois.
  • 18 Nov 2024 According to an Immatics media release, Based on the Phase 1b data and discussions with the U.S. Food and Drug Administration, Immatics is on track to commence SUPRAME, the registration-enabling Phase 3 randomized-controlled clinical trial in melanoma for IMA203, in December 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top